|
Jun 3
|
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
|
|
May 30
|
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
|
|
May 28
|
Biogen and City Therapeutics to develop RNAi therapy
|
|
May 28
|
Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal
|
|
May 27
|
Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal
|
|
May 27
|
Biogen strikes RNAi deal with City; Aurion withdraws IPO
|
|
May 27
|
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
|
|
Apr 24
|
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
|
|
Apr 24
|
Can Biogen Keep the Beat Streak Alive This Earnings Season?
|
|
Apr 24
|
Biogen’s Friedreich’s ataxia treatment authorised in UK
|
|
Feb 19
|
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
|
|
Feb 19
|
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative
|
|
Feb 18
|
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
|
|
Feb 18
|
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
|
|
Feb 18
|
Biogen buys rights to Stoke’s rare epilepsy drug
|
|
Feb 13
|
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
|
|
Feb 13
|
Biogen Still Offering Value, RBC Says
|
|
Feb 13
|
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
|
|
Feb 13
|
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
|
|
Feb 13
|
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
|